Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT03645928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Study identification
- NCT ID
- NCT03645928
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Lifileucel Biological
- LN-145 Biological
- Pembrolizumab Drug
- LN-145-S1 Biological
- Ipilimumab Drug
- Nivolumab Drug
- Nivolumab-relatlimab Drug
- Cisplatin Drug
- Carboplatin Drug
- Paclitaxel Drug
- Nab paclitaxel Drug
- Pemetrexed Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2019 (Actual)
- Primary completion
- Feb 20, 2026 (Actual)
- Completion
- Feb 20, 2026 (Actual)
- Last update posted
- May 15, 2026
2019 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92093 | — |
| University of Southern California | Los Angeles | California | 90007 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of Colorado | Denver | Colorado | 80045 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32610 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Louisville | Louisville | Kentucky | 40292 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| MD Anderson at Cooper | Camden | New Jersey | 08103 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| Ohio State University | Columbus | Ohio | 43201 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03645928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03645928 live on ClinicalTrials.gov.